Polymer Factory (POLYMER) Q2 2025 earnings summary

Executive summary

• Net sales rose 358% in Q2 2025 year-over-year, with earnings improving by 87% compared to Q2 2024.

• Cost reductions of 27% contributed to improved financial balance and reduced losses.

• Strategic supply agreements signed with Bruker and a global biopharma leader, plus a major order from an international energy company.

• SpheriCal® sales surged approximately 740% year-over-year, indicating strong market acceptance.

• Directed share issue completed to increase working capital.

Financial highlights

• Q2 2025 net sales: KSEK 903 (Q2 2024: KSEK 197); YTD net sales: KSEK 1,251 (YTD 2024: KSEK 592).

• Q2 2025 loss: KSEK -165 (Q2 2024: KSEK -1,317); YTD loss: KSEK -1,045 (YTD 2024: KSEK -2,567).

• Q2 2025 EPS: SEK -0.01 (Q2 2024: SEK -0.12); YTD EPS: SEK -0.08 (YTD 2024: SEK -0.24).

• Cash and bank at June 30, 2025: KSEK 1,630; equity: KSEK 3,924.

• Cash flow for Q2 2025: KSEK -431 (Q2 2024: KSEK -1,416); YTD: KSEK -85 (YTD 2024: KSEK -3,006).

Outlook and guidance

• Targeting positive cash flow and profitability in the near term through proactive customer engagement and cost structure adjustments.

• Board notes risk of insufficient financing over the next 12 months if sales or cost reductions do not meet expectations or if capital is not raised.